BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

NCT03944356 · clinicaltrials.gov ↗

COMPLETED

Status

232

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Dabrafenib and Trametinib

Sponsor

EuMelaReg gGmbH